Arcus Biosciences (RCUS) PT Raised to $46 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Arcus Biosciences (RCUS) PT Raised to $46 at Citi
October 24, 2024 7:30 AM EDT
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC)
Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment
Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today
... More
October 22, 2024 4:05 PM EDT
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Companys financial results and pipeline update for the quarter ended September 30th, 2024.
Investors... More
